Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women

Robert E. Pyke, MD, PhD, Anita H. Clayton, MD The Journal of Sexual Medicine. Volume 16, Issue 12, December 2019, Pages 1885-1894. Link

S1 Biopharma Supports FDA Advisory Committee’s Recommendation to Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder

NEW YORK, June 5, 2015 /PRNewswire/ — Yesterday’s FDA Advisory Committee recommendation for the approval of flibanserin was a landmark step for women’s health, addressing the important unmet medical need for women living with hypoactive sexual desire disorder, or HSDD.…

Sexual desire and hypoactive sexual desire disorder in women. Introduction and overview. Standard operating procedure (SOP Part 1).

Bitzer J, Giraldi A, Pfaus J. J Sex Med. 2013 Jan;10(1):36-49. doi: 10.1111/j.1743-6109.2012.02818.x. Epub 2012 Sep 13. Link

Hypoactive sexual desire disorder in women: treatment options beyond testosterone and approaches to communicating with patients on sexual health.

Lodise NM. Pharmacotherapy. 2013 Apr;33(4):411-21. doi: 10.1002/phar.1209. Link

The Scientist | Opinion: Sexual Dysfunction Matters

S1 Biopharma Doses First Patients in Phase 2a Clinical Trial of Lorexys in Premenopausal Women with HSDD

Activity of Lorexys Requires Precise Ratio of Active Components, Trazodone and Bupropion JERSEY CITY, N.J., July 29, 2013 — S1 Biopharma, Inc., a developer of first-in-class drugs for sexual dysfunction in women and men, today announced enrollment and dosing of premenopausal…

BioWorld | S1 Biopharma Aims for Female Viagra for HSDD Sans Hormones

S1 Biopharma Expands Focus to Include Male Sexual Health

Developer of the Only Non-Hormonal Therapy for HSDD in Women Announces S1P-205, the Only Therapy for HSDD in Men Jersey City, NJ — May 14, 2012 —S1 Biopharma, an early-stage biopharmaceutical company developing therapeutic solutions for Hypoactive Sexual Desire Disorder…